Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05269628 · ClinicalTrials.gov registry record · Phase 2
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
A Phase 2 study of Pain and Multiple Sclerosis, sponsored by Tiffany J. Braley, MD, MS.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
- 1
- Study location
NCT05269628: Recruiting Phase 2 study of Pain and Multiple Sclerosis, sponsored by Tiffany J. Braley, MD, MS.
NCT05269628 is a Phase 2 study of Pain and Multiple Sclerosis that is actively recruiting participants, run by Tiffany J. Braley, MD, MS. The registered enrollment target is 166 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05269628, a Phase 2 study of Pain and Multiple Sclerosis, is actively recruiting participants, sponsored by Tiffany J. Braley, MD, MS.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to compare the effects of cannabidiol (CBD), tetrahydrocannabinol (THC), or both, on sleep and pain in persons with multiple sclerosis (MS). Little is known about how CBD and/or THC may help sleep, reduce pain, or perhaps even treat pain through better sleep.
Primary Outcome
Measured with in-laboratory polysomnography, reported as average length of continuous bouts of sleep, for each sleep stage and total sleep (in minutes).
Conditions Studied
Interventions
- DRUG Cannabidiol (CBD)
- DRUG Tetrahydrocannabinol (THC)
- DRUG Placebo CBD
- DRUG Placebo THC
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2022-03-25 |
| Est. Completion | 2027-08-30 |
| Phase | Phase 2 |
What NCT05269628 shows while recruiting
NCT05269628 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (45% lower).
The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 4 interventions - of which Cannabidiol (CBD) is the first listed.
NCT05269628 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05269628 about?
NCT05269628 is a clinical study titled "Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype". The purpose of this research study is to compare the effects of cannabidiol (CBD), tetrahydrocannabinol (THC), or both, on sleep and pain in persons with multiple sclerosis (MS). Little is known about how CBD and/or THC may help sleep, reduce pain, or perhaps even treat pain through better sleep.
What is the current status of trial NCT05269628?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2022-03-25. Estimated completion is 2027-08-30.
What conditions does trial NCT05269628 study?
This clinical trial studies the following conditions: Pain, Multiple Sclerosis, Sleep.
What interventions are being tested in trial NCT05269628?
The interventions under investigation include: Cannabidiol (CBD) (DRUG), Tetrahydrocannabinol (THC) (DRUG), Placebo CBD (DRUG), Placebo THC (DRUG).
Who is sponsoring clinical trial NCT05269628?
This trial is sponsored by Tiffany J. Braley, MD, MS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05269628 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05269628's enrollment target sits among peer trials
166 108th of 374 higher than 267 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Neural Correlates of Hypoalgesia Driven by Observation
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
-
Pain After Buffered Vs Non Buffered Articaine
RECRUITING · Phase 2
-
Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Neuropathy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI